← Markets

MiniMed Group, Inc. Common Stock

MMED · NASDAQ

Market closed$16.93$1.05 (+6.61%)After hours $16.90 · -0.18%

Key statistics

Previous close$15.88
Open$15.71
Day high$17.15
Day low$15.67
52-week high$20.48
52-week low$10.65
Market cap4.75B
Volume2.38M
Average volume944.16K
P/E ratio-21.85
Forward P/E—
EPS-0.78
Dividend yield0.00%

Market context

Why it moved

MMED surged following a significant insider headline that sparked strong bullish momentum, with options traders piling into call flow and targeting further upside as the stock attracted heavy speculative interest.

FacebookInstagramUnrThedartmouthMarketbeat

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026MiniMed Group surged nearly 6.6% on well-above-average volume — more than double the daily norm — as Wall Street analysts continued to back the recently spun-off diabetes tech company. Bank of America reiterated its Buy rating with a $20 target, citing the upcoming Fit system and Vivera patch-based platform as key growth drivers, while BTIG maintained a Buy with a $25 target. Despite a mixed most-recent quarter — revenue up 15.6% YoY to $837M but EPS missing estimates — the consensus remains 'Moderate Buy' with an average target of $21.33, well above current levels. In after-hours trading, shares are holding essentially flat near $16.90.

6.6121

July 16, 2026MiniMed Group advanced as the broader healthcare sector rallied sharply, lifted by UnitedHealth Group's strong Q2 earnings beat and raised full-year guidance, which boosted sentiment across medical device and equipment names. Adding to the tailwind, Abbott Laboratories surged over 12% on its own Q2 results, reinforcing investor confidence in diabetes care—a space where MiniMed competes directly with its integrated insulin pump, CGM, and algorithm ecosystem following its spin-off from Medtronic earlier this year.

2.9831

July 10, 2026MiniMed Group closed essentially flat on Thursday, finishing modestly higher as investors weighed a constructive analyst backdrop against a recent earnings miss and a challenging macro environment. Benchmark reiterated its Buy rating and $20 price target following a 10-K model update, highlighting management's guidance for ~10% organic revenue growth and ~16% adjusted EBITDA margins in fiscal 2027, with upcoming catalysts including an FDA submission for the Fit patch pump and the launch of the MiniMed Flex AID system. The stock holds a consensus "Moderate Buy" from 15 analysts with an average price target of $21.33, though it remains under pressure after Q4 EPS of -$0.68 missed estimates by $0.46. In after-hours trading, shares gained an additional ~2.5%, outpacing the broader healthcare sector ETF (XLV), which was flat in extended trading. Multiple senior executives, including the CEO and CFO, received large RSU grants under the 2026 Long Term Incentive Plan in early July, signaling management retention and longer-term alignment with shareholders.

0.1997

July 8, 2026MiniMed Group declined as broader market risk-off sentiment weighed on equities, with oil prices surging over 5% after President Trump declared the U.S.-Iran peace framework 'over,' reigniting geopolitical tensions and inflation fears. Adding to the backdrop, MiniMed saw a wave of insider RSU grants this week — including a 297,618-share award to the CEO and grants to the CFO, CAO, and multiple SVPs under its 2026 Long Term Incentive Plan — signaling management retention focus, even as healthcare sector sentiment remained broadly resilient, with XLV posting a 6.6% gain in June and outperforming most sectors.

-2.2772

July 8, 2026MiniMed Group edged higher, closing with a modest gain as the company disclosed a broad wave of executive RSU grants under its 2026 Long Term Incentive Plan, covering the CEO, CFO, CAO, and several senior vice presidents. The grants signal management retention focus and longer-term alignment with company performance. MiniMed shares also benefited from a favorable sector backdrop, with the healthcare ETF (XLV) approaching its 52-week high amid a multi-week rotation into healthcare and away from technology, as health care has been one of the S&P 500's top-performing sectors recently.

0.5232

July 2, 2026MiniMed Group shares rose amid a strong healthcare sector backdrop, with the XLV sector ETF touching a 52-week high, as investors continued digesting the company's recently filed FY2026 10-K and Q4 earnings beat. The diabetes technology spinout from Medtronic reported $837 million in Q4 revenue at 8.7% organic growth and guided for ~10% organic growth in FY2027, while analyst commentary remains split — Benchmark maintaining a Buy with a $20 target versus Piper Sandler's Neutral at $16. Recent governance moves, including the board additions of Alcon CEO David Endicott and Medtronic executive Linnea Burman, signal ongoing efforts to build credibility as a newly independent public company, though investors continue to weigh the $333 million trailing net loss and a cash runway of under one year against the compelling revenue growth story.

2.6333

July 2, 2026MiniMed shares rose, buoyed by a wave of governance and financial disclosures that reinforced its identity as a standalone diabetes technology company. The company expanded its board to 11 members by appointing Alcon CEO David Endicott and Medtronic executive Linnea Burman, signaling a push for independent leadership depth even as Medtronic remains majority shareholder. This follows MiniMed's fiscal 2026 10-K disclosing $3.1B in revenue — up from $2.7B — though net losses widened to $317M, reflecting heavy R&D investment as it competes in the $19B+ global diabetes tech market.

1.6054

July 1, 2026MiniMed Group edged modestly higher, buoyed by a confluence of index inclusion news and governance developments. The company was added to the Russell 2000 and Russell 2000 Value benchmarks, a catalyst that can drive passive fund inflows. Simultaneously, the company expanded its board to 11 members with the appointments of Alcon CEO David Endicott and Medtronic executive Linnea Burman, signaling a strengthening of independent leadership. The backdrop is further supported by the company's fiscal 2026 10-K filing, which showed revenue growing to $3.1 billion from $2.7 billion, though net losses widened to $317 million, and analyst consensus sits well above current trading levels with an average price target of ~$20.91.

0.4704

AboutLawsuits.com · July 17, 2026Lawsuit Claims Medtronic MiniMed Insulin Pump Malfunction Resulted in Diabetic ComaKavout | AI · July 16, 2026Is Medtronic's MiniMed Spin-Off a Smart Bet for InvestorsMedTech Dive · June 3, 2026MiniMed expands Abbott partnership to add dual glucose-ketone sensorStock Titan · June 3, 2026Diabetes tech firm MiniMed tops $3.1B sales, sees 10% organic growth in FY27Simply Wall Street · May 26, 2026MiniMed Study Highlights Algorithm Strength And Raises Questions On Depressed ValuationMedTech Dive · April 21, 2026MiniMed posts double-digit sales growth, widening net lossStock Titan · April 13, 2026MiniMed sets June 3 webcast for Q4 and fiscal 2026 resultsInvesting.com · March 9, 2026MiniMed closes $560M IPO, Medtronic retains 90% stake
Mt Newswire · March 31, 2026MiniMed Likely to Ride on Pipeline Growth, BofA Says

Peers

S&P 500SPX · $7,457.69-1.01%DexCom, Inc.DXCM · $76.65-1.71%Insulet Corp.PODD · $164.06-0.23%Tandem Diabetes Care, Inc.TNDM · $17.08+4.85%Abbott LaboratoriesABT · $100.67+1.86%Medtronic plcMDT · $83.20-0.43%Becton, Dickinson and CompanyBDX · $158.17-1.10%Intuitive Surgical, Inc.ISRG · $345.42-14.15%Alcon Inc.ALC.SW · 56.70-0.42%Merit Medical Systems, Inc.MMSI · $73.99-2.06%Bausch + Lomb CorporationBLCO · $16.26-3.27%Haemonetics CorporationHAE · $77.86-0.82%